Literature DB >> 16506634

Locoregional therapies for glioma.

Adam N Mamelak1.   

Abstract

Glioma is the most common form of primary brain tumor, as well as the most lethal. Primary treatment strategies for glioma, including cytoreductive surgery, external-beam irradiation, and systemic chemotherapy have had generally disappointing results for these tumors. Limitations of these approaches include tumor invasion into functional brain tissue, lack of chemosensitivity, and shortcomings of systemic delivery. Recent attention has focused on locoregional strategies for treatment, as well as new methods for delivering therapy. Identification of tumor-specific surface targets, biologic agents, and more sophisticated means to deliver macromolecules to the brain is offering new promise in the treatment of these tumors. This paper will review the current state of the art of available locoregional therapies for glioma, with a particular focus on convection-enhanced delivery, targeted toxin, and other biologic strategies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16506634

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN: 0890-9091            Impact factor:   2.990


  3 in total

Review 1.  Emerging treatments and gene expression profiling in high-risk medulloblastoma.

Authors:  Iacopo Sardi; Duccio Cavalieri; Maura Massimino
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

2.  A comprehensive strategy to discover inhibitors of the translesion synthesis DNA polymerase κ.

Authors:  Kinrin Yamanaka; Dorjbal Dorjsuren; Robert L Eoff; Martin Egli; David J Maloney; Ajit Jadhav; Anton Simeonov; R Stephen Lloyd
Journal:  PLoS One       Date:  2012-10-08       Impact factor: 3.240

3.  Automated Steerable Path Planning for Deep Brain Stimulation Safeguarding Fiber Tracts and Deep Gray Matter Nuclei.

Authors:  Alice Segato; Valentina Pieri; Alberto Favaro; Marco Riva; Andrea Falini; Elena De Momi; Antonella Castellano
Journal:  Front Robot AI       Date:  2019-08-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.